Advertisement
Singapore markets open in 28 minutes

  • Straits Times Index

    3,187.66
    +32.97 (+1.05%)
     

  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     

  • Dow

    37,775.38
    +22.07 (+0.06%)
     

  • Nasdaq

    15,601.50
    -81.87 (-0.52%)
     

  • Bitcoin USD

    63,001.36
    +1,827.68 (+2.99%)
     

  • CMC Crypto 200

    1,302.81
    +417.28 (+46.67%)
     

  • FTSE 100

    7,877.05
    +29.06 (+0.37%)
     

  • Gold

    2,389.20
    -8.80 (-0.37%)
     

  • Crude Oil

    82.52
    -0.21 (-0.25%)
     

  • 10-Yr Bond

    4.6470
    +0.0620 (+1.35%)
     

  • Nikkei

    37,505.53
    -574.17 (-1.51%)
     

  • Hang Seng

    16,385.87
    +134.03 (+0.82%)
     

  • FTSE Bursa Malaysia

    1,544.76
    +4.34 (+0.28%)
     

  • Jakarta Composite Index

    7,166.81
    -7,130.84 (-49.87%)
     

  • PSE Index

    6,523.19
    +73.15 (+1.13%)
     

Why Shares of Adaptimmune Therapeutics Jumped Tuesday

Jim Halley, The Motley Fool
Updated ·1-min read
Why Shares of Adaptimmune Therapeutics Jumped Tuesday

Shares of Adaptimmune Therapeutics (NASDAQ: ADAP) were up as much as 9.7% early Tuesday after the clinical-stage biotech announced that it had reached an agreement with GSK (NYSE: GSK) to return the rights to Adaptimmune's PRAME and NY-ESO cell therapy programs. Adaptimmune focuses on therapies to treat cancer in solid tumors through its SPEAR (for Specific Peptide Enhanced Affinity Receptor) T-cell platform. The company has four SPEAR T-cells in trials: MAGE-A10, MAGE-A4, AFP, and NY-ESO.

Continue reading